- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02731885
Food Effect on Pharmacokinetic Parameters of ABX464
An Open, Randomized Study, to Investigate the Potential Food Effect on Pharmacokinetic Parameters of ABX464 Administered Orally to Healthy Male Subjects
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
This is a phase I, single-center, open-label, two-treatment, food-effect, randomized study in 40 healthy Caucasian male subjects in order to determine the impact of the food on the absorption of the ABX464.
The two different treatments are the followings:
- Treatment A = 50mg of ABX464 (two 25mg capsules) /Fasted
- Treatment B = 50mg of ABX464 (two 25mg capsules) / Fed
This study consists of two groups:
- Group 1 - single dose assessments, two-period, two-treatment, cross-over: 20 subjects will receive a single dose of 50mg of ABX464 in fed and fasted condition, separated by a wash-out period of at least 45 days.
- Group 2 - multiple dose assessments: 20 subjects will receive 50mg of ABX464 every 3 days during 10 days in fasted or fed condition.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 1
Kontakte und Standorte
Studienorte
-
-
Phoenix
-
Sayed Hossen road, Phoenix, Mauritius
- CAP Research
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Healthy Caucasian male subjects, 18-55 years of age
- Body Mass Index (BMI) of 17-28 kg/m².
- Certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination)
Normal vital signs after 10 minutes resting in supine position:
90 mmHg < systolic blood pressure < 140 mmHg, 50 mmHg < diastolic blood pressure < 90 mmHg, 40 bpm < heart rate < 100 bpm.
- Normal automatic 12-lead ECG (incomplete right bundle branch block can be accepted) or judged as non clinically significant.
- Clinical laboratory tests (hematology, blood chemistry, and urinalysis) must be within normal limits or clinically acceptable to Investigator and Sponsor.
- Subjects must be willing to give written informed consent prior to study enrollment and be able to adhere to restrictions and examination schedules.
Exclusion Criteria:
- Individuals with a history of any significant medical disorder which requires a physician's care (cardiovascular, pulmonary, gastro-intestinal, hepatic, renal, metabolic, hematological, neurologic, psychiatric, systemic, or infectious disease; any acute infectious disease or signs of acute illness)
- Frequent headaches and / or migraine, recurrent nausea and / or vomiting (more than twice a month).
- Presence or history of drug allergy, or allergic disease diagnosed and treated by a physician.
- Individuals who have a history of any clinically significant local or systemic infectious disease within 4 weeks prior to drug administration.
- Any individual who does not comply with the requirement that he should not have used any drugs other than paracetamol for at least 2 weeks prior to the study nor alcohol within 48 hours prior to drug administration.
- Individuals who are positive for hepatitis B virus, hepatitis C virus or HIV.
- History or presence of drug or alcohol abuse (positive urine drug screen, positive alcohol breath test).
- Smoking more than 5 cigarettes or equivalent / day, unable to stop smoking during the study.
- Excessive consumption of beverages with xanthine bases (> 4 cups or glasses / day).
- Subject who will likely be unable to eat entirely the standard high fat breakfast within the allocated time.
- Individuals who have donated blood within the preceding 3 months.
- Individuals who refuse to use an effective method of contraception from the beginning of the study and until 3 months after dosing.
- Individuals with forfeiture of freedom by an administrative or legal obligation or under guardianship
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Crossover-Aufgabe
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Fasted Conditions
50mg of ABX464 (two 25mg capsules) /Fasted
|
Two-periods, subjects received a single dose of 50mg of ABX464 in fed and fasted condition, separated by a wash-out period of at least 45 days.
Subjects received 50mg of ABX464 every 3 days during 10 days in fasted or fed condition.
|
|
Experimental: Fed Conditions
50mg of ABX464 (two 25mg capsules) /Fed
|
Two-periods, subjects received a single dose of 50mg of ABX464 in fed and fasted condition, separated by a wash-out period of at least 45 days.
Subjects received 50mg of ABX464 every 3 days during 10 days in fasted or fed condition.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Area under the plasma concentration versus time curve (AUC) of single oral dose of 50mg of ABX464 in fed or fasted condition.
Zeitfenster: 45 days
|
45 days
|
|
Peak Plasma Concentration (Cmax) of single oral dose of 50mg of ABX464 in fed or fasted condition.
Zeitfenster: 45 days
|
45 days
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Area under the plasma concentration versus time curve (AUC) of repeated doses of 50 mg of ABX464 in fed or fasted conditions
Zeitfenster: 10 days
|
10 days
|
|
Peak Plasma Concentration (Cmax) of repeated doses of 50 mg of ABX464 in fed or fasted conditions
Zeitfenster: 10 days
|
10 days
|
|
Number of Subjects with treatment-related adverse events as assessed by CTCAE v4.0
Zeitfenster: Up to 45 days
|
Up to 45 days
|
Mitarbeiter und Ermittler
Sponsor
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Andere Studien-ID-Nummern
- ABX464-FE-001
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .